Forschung

A 2016 study found that a single dose of shrooms can significantly reduce cancer patients' fear of death, and a new follow-up study has found that these benefits can last for years. Nearly five years ago, a team of researchers conducted a landmark trial exploring...

Summary: Psychedelics, such as psilocybin, provide lasting improvements in mood and feelings of social connectedness after the effect of the drug has worn off. Source: Yale People who had recently used psychedelics such as psilocybin report a sustained improvement in...

Abstract This article provides an ethical analysis of psychedelic research involving disorders of consciousness patients. We apply two internationally accepted approaches for analyzing the ethics of human research, the Value-Validity Framework and Component Analysis,...

Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science Abstract After two decades of quiescence, clinical psychedelic research re-started in the 1990s and is rapidly accelerating. Early...

A comprehensive review of research literature on Psychedelics, for the lay person (2019) In this post you are going to learn everything researchers have discovered to date, on both Psychedelics as well as Non-psychedelic hallucinogens. We’ll share findings in research...

New research from King's College London has found that MDMA, the main ingredient in ecstasy, causes people to cooperate better—but only with trustworthy people. In the first study to look in detail at how MDMA impacts cooperative behaviour the researchers also...

Das Global Ayahuasca Project ist ein multidisziplinäres Studienprojekt mit Sitz an der Universität Melbourne, Australien, und in Zusammenarbeit mit Wissenschaftlern aus Australien, Brasilien, Spanien, Tschechien und der Schweiz. Dieses Forschungsprojekt...

Wir leiten hiermit gerne den Aufruf zu einer qualitativen Untersuchung zum Thema substanzunterstützte Therapien weiter. Die Forschungsarbeit wird nicht von der Psychedelischen Gesellschaft durchgeführt. Bei Interesse könnt Ihr Euch mit Charis Heidenreich in Verbindung setzen.

Die doppelblind-placebokontrollierte Phase-2-Pilotstudie an 26 Teilnehmern wurde von der Multidisziplinären Vereinigung für Psychedelische Studien (MAPS) gesponsert. Einen Monat nach der zweiten eintägigen MDMA-Sitzung erfüllten 68% der Probanden in der voll dosierten MDMA-Gruppe nicht mehr die Kriterien für die Ausgangsdiagnose im Vergleich zu 29% in der niedrig dosierten MDMA Kontrollgruppe. Der Umfang der Behandlung umfasste 13,5 Stunden nicht-medikamentöse Psychotherapie und 16 Stunden (zwei eintägige Sitzungen mit Substanzunterstützung) entweder mit voll (125mg) oder niedrig (20mg und 75mg) dosierter MDMA-unterstützter Psychotherapie. Im Durchschnitt hielten die positiven Effekte auch ein Jahr später noch an.

The survey will ask about your background and story of the use of LSD and/or Psilocybin, your motivations, your health and the impact you think LSD and/or Psilocybin have had on your health and well-being. The survey also contains questions about adverse effects from the use of LSD and/or Psilocybin. The purpose of this survey is to gather information and understanding primarily about the use of so-called micro dosing of lysergic acid diethylamide (LSD or LSD25) and Psilocybin (the active substance in psychedelic fungi, such as magic mushrooms). The aim of the study is to investigate the effects and adverse effects on mental health at micro-dosing of LSD and Psilocybin.

Scientific methods based upon materialistic philosophy have been highly successful in not only increasing our understanding of nature but also in bringing greater control and freedom through advances in technology. However, the nearly absolute dominance of materialism...

Vancouver is one of 16 locations in the United States, Canada and Israel where clinicians hope to demonstrate that a drug historically associated with gurus and raves can revolutionize psychotherapy and trauma treatment. The B.C. Centre on Substance Use will conduct...

Psilocybin, the active compound in magic mushrooms, could make people feel more connected to nature and less likely to endorse authoritarian views, according to new research from the Psychedelic Research Group at Imperial College London.The new study, published in the...

It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN)...

Psychedelic therapy is going through something of a revival right now, and we may now know how one such hallucinogenic drug is seemingly able to alleviate symptoms of depression. Psilocybin, the active compound in magic mushrooms, has long been known to deliver...

In der aktuellen Ausgabe von "Psychotherapy and Psychosomatics" offenbart eine neue Analyse Einsichten in Langzeiteffekte von Antidepressiva. Neun Jahre nach der Behandlung waren die depressiven Symptome deutlich erhöht gegenüber der Behandlung ohne Medikamente. Weder...

Nonprofit seeks funding for phase III trials after Food and Drug Administration grants MDMA "breakthrough therapy" status One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has...

The altered state of consciousness and temporary lack of ego that results from using psychedelic drugs could help some mental health patients recover from their symptoms, according to academics at the University of Adelaide. Researchers in the University's Department...

Der halluzinogene Wirkstoff Psilocybin gilt als Kandidat für Therapien gegen Depression und andere Leiden. Nun klärten deutsche Forscher seine Herstellung auf. Quelle: http://www.spektrum.de/news/wirkstoff-von-magic-mushrooms-biotechnisch-hergestellt/1495423

After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and...